The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M., Chun, J. J. M., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
“The latter, however, introduces a cautionary note owing to an early clinical trial of an agonist anti-CD28 (TGN1412) in which severe toxicities and even death resulted from unexpected cytokine releas”
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
“…these toxicities, especially cytokine release syndrome (CRS), were reminiscent of those seen in a study in which all 6 healthy young male volunteers who received a low dose of TGN1412 (a superagonist monoclonal antibody to CD28) required critical care for the rapid onset of multiorgan failure [7].”
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
“CRS has classically been associated with therapeutic mAb infusions, most notably anti-CD3 (OKT3), anti-CD52 (alemtuzumab),19 anti-CD20 (rituximab), and the CD28 super-agonist, TGN1412.”
BackgroundInfluentialMorgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
“CTLA-4 and CTLA-4‐Ig fusion protein (abatacept) have proved their efficacy in the treatment of cancer and RA, respectively (121‐124), manipulations of co-stimulatory signals can result in tragic consequences ( 125 ).”
BackgroundCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
“The experimental drug TGN1412, which had been shown in pre-clinical animal studies to induce Treg cells, caused systemic release of pro-inflammatory cytokines in six volunteers (Hünig, 2012; Suntharalingam et al., 2006).”
BackgroundLost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Kellum, J. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1655 · Cited by 828
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Cytokine storms: understanding COVID-19
Mangalmurti, N., & Hunter, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.017 · Cited by 698
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
The perfect mix: recent progress in adjuvant research
Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 620
“However, it is certainly safer to inhibit co-stimulatory pathways than to directly activate them, and the recent outcome of a trial using a super CD28-agonist (the TGN1412 antibod”
BackgroundThe signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Austin, P. J., & Moalem-Taylor, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.013 · Cited by 607
“, 2009), although clinical trials with the Treg activator, TGN1412, led to severe adverse effects (Suntharalingam et al., 2006).”
Laboratory mice born to wild mice have natural microbiota and model human immune responses
Rosshart, S. P., Herz, J., Vassallo, B. G., Hunter, A., Wall, M. K., Badger, J. H., McCulloch, J. A., Anastasakis, D. G., Sarshad, A. A., Leonardi, I., et al. (2019) · Science · doi:10.1126/science.aaw4361 · Cited by 572
“Rather, it resulted in an unexpected and devastating activation of inflammatory T cell subsets followed by a life-threatening cytokine storm (29).”
BackgroundMethodInfluentialThe pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“[1378] Suntharalingam, G.”
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., & Remick, D. G. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130327 · Cited by 549
“The potential significance of the B7:CD28 pathway in the innate response was emphasized by a clinical trial (18) of a CD28 monoclonal agonist antibody.”
BackgroundOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
“This combination does, however, have the potential for uncontrolled proliferation and activation of the CAR-T cells (179) and will need to be examined using careful dose escalation studies and – ideally – with other safety interventions in place (see ‘Increasing the safety of CAR-T cells’).”
BackgroundIntratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim, J. S., Lee, J. Y., Yang, J. W., Lee, K. H., Effenberger, M., Szpirt, W., Kronbichler, A., & Shin, J. I. (2021) · Theranostics · doi:10.7150/thno.49713 · Cited by 463
“In addition, acute increases in various cytokines were also noted in the early phase: tumor necrosis factor-alpha (TNF-α) was observed within an hour, followed by IL-1 [8].”
BackgroundInfluentialClinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 453
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M., & Kobold, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 440
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
“Another earlier example of a T cell-engaging immunotherapy is the superagonist anti-CD28 monoclonal antibody TGN1412, which directly activates CD4 effector memory T cells and which induced rapid CSS within minutes after infusion in six healthy volunteers [65].”
BackgroundAcute-on-chronic liver failure in cirrhosis
Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U., García-Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 434
Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100209 · Cited by 433
“This approach has been tested in a clinical trial using agonistic -CD28 (Suntharalingam et al., 2006) and in preclinical models with high doses of IL-2, IL-2/–IL-2 complex, or Flt3-L (Swee et al.”
MethodHuman T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 412
“Thispoint wasmostdramatically illustrated ina phase I clinical trial testing TGN1412, a superagonistic CD28 antibody (Ab) (Suntharalingam et al., 2006).”
BackgroundCytokines as biomarkers of nanoparticle immunotoxicity
Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 407
Targeting the NLRP3 Inflammasome in Severe COVID-19
Freeman, T. L., & Swartz, T. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01518 · Cited by 405
Interleukin (IL-6) Immunotherapy
Tanaka, T., Narazaki, M., & Kishimoto, T. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 407
“Surgery-related complications, adrenal insufficiency, pulmonary embolism, and aortic aneurysm can also lead to SIRS, and a biological drug against CD28 was also reported to induce SIRS (Suntharalingam et al. 2006).”
BackgroundThistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
“The trial opened in 2007 after significant delays during the regulatory process due to issues reported in other immune-based trials [26, 27].”
BackgroundGrading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
“Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.”
BackgroundGargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 395
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392
“disease (4), or idiopathic or drug induced (1), respectively.”
BackgroundCytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines
Fara, A., Mitrev, Z., Rosalia, R. A., & Assas, B. M. (2020) · Open Biology · doi:10.1098/rsob.200160 · Cited by 369
Capillary leak syndrome: etiologies, pathophysiology, and management
Siddall, E., Khatri, M., & Radhakrishnan, J. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.029 · Cited by 364
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“absence of infection (Goris 1990; Suntharalingam et al. 2006).”
BackgroundThe promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Review: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356
de Jager, W., Hoppenreijs, E. P. A. H., Wulffraat, N. M., Wedderburn, L. R., Kuis, W., & Prakken, B. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.061853 · Cited by 347
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Zushin, P.-J. H., Mukherjee, S., & Wu, J. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175824 · Cited by 347
“Preclinical experiments showed great efficacy in a BALB/c mouse model of B-CLL, but in humans, a low dose (1/500th of the safe dose in mice) induced a massive cytokine storm, resulting in organ failure and hospitalization (8).”
BackgroundBispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
“However, activation of costimulatory receptors can lead to unbridled inflammatory responses with life-threatening consequences.(7) An understanding of T cell costimulation is therefore critical for the development of safe and effective adoptive T cell therapies, including those employing chimeric antigen receptors CAR…”
BackgroundGoing viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
“‘Testing of the feasibility of this approach’ can only be carried out in clinical trials, as preclinical models have proven time and again to be insufficiently predictive of both efficacy and toxicity in humans (20, 21).”
BackgroundCRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Regulatory T cells ameliorate cardiac remodeling after myocardial infarction
Tang, T.-T., Yuan, J., Zhu, Z.-F., Zhang, W.-C., Xiao, H., Xia, N., Yan, X.-X., Nie, S.-F., Liu, J., Zhou, S.-F., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-011-0232-6 · Cited by 318
Mechanism of cellular rejection in transplantation
Ingulli, E. (2010) · Pediatric Nephrology · doi:10.1007/s00467-008-1020-x · Cited by 313
Qing, S., Lyu, C., Zhu, L., Pan, C., Wang, S., Li, F., Wang, J., Yue, H., Gao, X., Jia, R., et al. (2020) · Advanced Materials · doi:10.1002/adma.202002085 · Cited by 309
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
“Thus, antibodies deemed safe based on nonhuman primate species evaluation have showndramatic toxicity in humans, contributed in part by differences in FcγRaffinities and distribution between the species (24).”
BackgroundB7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 307
“9 Suntharalingam, G. et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.”
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
“Preclinical studies in rats, non-human primates, and cultures of human cells failed to predict nearly lethal cytokine release syndrome in the six healthy volunteers first dosed with TeGenero's CD28SA TGN1412 [101].”
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
“Progress in this approach was initially slow, owing to the clinical failure of the CD28 super-agonist mAb TGN1412 that induced “cytokine storms” and life-threatening organ failure in 17% of patients (89).”
BackgroundCytokine Storm—Definition, Causes, and Implications
Jarczak, D., & Nierhaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911740 · Cited by 304
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
“They also illustrate the challenges of targeting costimulation to tumor-reactive T cells, including tumor-infiltrating T cells, and the risks of systemic approaches when costimulation is not restricted to tumor-specific T cell”
BackgroundTherapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
“, was discontinued after causing unforeseen adverse effects in healthy individual”
BackgroundEastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
“One of the most striking features of the TGN1412-mediated ‘cytokine storm’ observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
BackgroundResultInfluentialOvercoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
“These symptoms were subsequently attributed to “on-target” effects of the CD28 agonist causing excessive cytokine release, leading to a severe shocklike syndrome (Suntharalingam et al., 2006).”
Clinical review: Blood purification for sepsis
Rimmel�, T., & Kellum, J. A. (2011) · Critical Care · doi:10.1186/cc9411 · Cited by 279
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
“A cytokine storm was recently reported in all six healthy volunteers who received a novel anti-CD28 monoclonal antibody in a phase I clinical trial, which presented initially as severe headache, lumbar myalgias, gastrointestinal symptoms, rigors, erythema, and peripheral vasodilation by 60–90 minutes after the infusio…”
BackgroundVimentin regulates activation of the NLRP3 inflammasome
dos Santos, G., Rogel, M. R., Baker, M. A., Troken, J. R., Urich, D., Morales-Nebreda, L., Sennello, J. A., Kutuzov, M. A., Sitikov, A., Davis, J. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7574 · Cited by 274
The science and medicine of human immunology
Pulendran, B., & Davis, M. M. (2020) · Science · doi:10.1126/science.aay4014 · Cited by 274
“One of the most notorious examples in recent years is theralizumab, an anti-CD28 antibody (29).”
BackgroundAnimal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting?
Dyson, A., & Singer, M. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181922bd3 · Cited by 273
“Sometimes, as graphically demonstrated by the unexpected cytokine storm witnessed in human volunteers given an anti-CD28 monoclonal antibody (108), preclinical studies may fail to highlight potentially life-threatening complications in humans.”
BackgroundBiomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Wang, Z., & Han, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0116-0 · Cited by 273
“Pathophysiology of CRS related to CAR-T cell therapy CRS is not restricted to CAR-T cell therapy and is associated with therapeutic monoclonal antibodies such as anti-CD3 (OKT3) [45], anti-CD20 (rituximab) [46],antiCD28 (TGN1412) [47], anti-CD52 (alemtuzumab) [48], CD3/CD19 bispecific antibody (blinatumomab) [49] and…”
BackgroundAdaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
“), regulation of cell surface markers of activation, signal transduction events, and proliferation [122,123].”
BackgroundAdvances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
(2008) · JAMA · doi:10.1001/jama.300.16.1887 · Cited by 261
“The observed cytokine storm following infusion had not been observed in the preclinical studies of TGN1412.(16) To obtain valuable results from the preclinical (toxicology) studies, a relevant test animal should not only be selected based on pharmacological activity and low immunogenicity, but suitable pharmacokinetic…”
BackgroundPrinciples of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Chodon, T., Comin-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 259
“Patients who experienced respiratory distress with the administration of non-cryopreserved TCR transgenic cells demonstrated an increase in circulating cytokines and chemokines, nevertheless lower than the levels noted in two clinical reported cases of life-threatening cytokine storm (32, 33).”
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 257
“This led to a systemic burst of pro-inflammatory cytokines with the individuals requiring life support [82].”
BackgroundIdiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
TGN1412: From Discovery to Disaster
Attarwala, H. (2010) · Journal of Young Pharmacists · doi:10.4103/0975-1483.66810 · Cited by 253
“When this antibody was tested in humans, it was immediately withdrawn from phase 1 clinical trials and volunteers had to be taken to intensive care unit 8 h after drug infusion due to multiorgan failure.[4]”
Regulation of Activated CD4+ T Cells by NK Cells via the Qa-1–NKG2A Inhibitory Pathway
Lu, L., Ikizawa, K., Hu, D., Werneck, M. B. F., Wucherpfennig, K. W., & Cantor, H. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.017 · Cited by 253
“Because these antibodies often retain stimulatory or costimulatory properties, a frequent outcome of their use is wholesale and sometimes massive release of cytokines, leading to a “cytokine storm” (Suntharalingam et al., 2006).”
BackgroundSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs · doi:10.4161/mabs.2.3.11782 · Cited by 250
Humanized immune system mouse models: progress, challenges and opportunities
Allen, T. M., Brehm, M. A., Bridges, S., Ferguson, S., Kumar, P., Mirochnitchenko, O., Palucka, K., Pelanda, R., Sanders-Beer, B., Shultz, L. D., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0416-z · Cited by 250
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant
Hafner, A. M., Corthésy, B., & Merkle, H. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.013 · Cited by 247
“Prominent examples are soluble factors like type I interferon (IFN) [4], tumor necrosis factor (TNF)-α, [5], or a CD28-specific monoclonal antibody mimicking CD80 or CD86 binding [6] (Fig.”
Background
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.